APOB and hypertriglyceridemia: With the positive results of the first large-scale outcome trial to focus on hypertriglyceridemic subjects (12), and the persistent post-hoc observation that individuals with a phenotype of raised triglyceride and low HDL cholesterol do appear to benefit in terms of relative risk reduction in the major fibrate trials (3), it may be that triglyceride-lowering to be effective needs to be deployed in people with the hypertriglyceridemia-driven disturbances in apoB metabolism described in this review.